IDEXX Laboratories, Inc. vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518.89 (market cap $40.43B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.79 (market cap $3.14B). The key difference: IDEXX Laboratories, Inc. is far larger — about 12.9× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| IDXX | SPHD | |
|---|---|---|
Market Cap | $40.43B | $3.14B |
Volume | 692,164 | 1,461,349 |
Sector | Health | — |
52-Week High | $766.68 | $53.55 |
52-Week Low | $504.70 | $46.96 |
Typical Hold Time | 46 Days | 125 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
SPHD trades at $48.71, up 1.08% with a bearish technical outlook showing 17 sell signals versus 4 buys. The ETF focuses on high dividend yield and low volatility S&P 500 stocks, offering monthly income distribution. Recent dividend payments of $0.20-$0.21 demonstrate consistent income generation, though technical indicators suggest near-term pressure.
While SPHD provides attractive monthly dividends for income-focused investors, the bearish technical signals and concerns about total return performance compared to peers like SCHD present near-term headwinds. The fund's low volatility mandate may provide defensive positioning during market uncertainty, but investors should weigh income benefits against potential capital appreciation limitations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →